Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Basic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, United States.
Front Public Health. 2023 May 4;11:1171243. doi: 10.3389/fpubh.2023.1171243. eCollection 2023.
This review examines the current literature to identify biomarkers of frailty across patients with solid tumors. We conducted the systematic review using preferred reporting items for systematic reviews and meta-analysis guidelines (PRISMA). PubMed, Web of Science, and Embase databases were searched from their inception to December 08, 2021, for reports of biomarkers and frailty. Two reviewers independently screened titles, abstracts, and full-text articles. A quality assessment was conducted using NHLBI Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, and Quality Assessment of Case-Control Studies. In total, 915 reports were screened, and 14 full-text articles were included in the review. Most studies included breast tumors, were cross-sectional in design, and measured biomarkers at baseline or pre-treatment. Frailty tools varied with Fried Frailty Phenotype and the geriatric assessment most frequently used. Increased inflammatory parameters (i.e., Interleukin-6, Neutrophil Lymphocyte Ratio, Glasgow Prognostic Score-2) were associated with frailty severity. Only six studies were rated as good quality using assessment ratings. Together, the small number of studies and heterogeneity in frailty assessment limited our ability to draw conclusions from the extant literature. Future research is needed to identify potential target biomarkers of frailty in cancer survivors that may aid in early detection and referral.
这篇综述检查了当前的文献，以确定实体瘤患者的虚弱相关生物标志物。我们使用系统评价和荟萃分析指南（PRISMA）的首选报告项目进行了系统评价。从建立到 2021 年 12 月 08 日，在 PubMed、Web of Science 和 Embase 数据库中搜索了关于生物标志物和虚弱的报告。两名审查员独立筛选标题、摘要和全文文章。使用 NHLBI 观察性队列和横断面研究质量评估工具以及病例对照研究质量评估工具对质量进行了评估。共筛选了 915 份报告，有 14 篇全文文章纳入了综述。大多数研究包括乳腺癌，设计为横断面，在基线或治疗前测量生物标志物。虚弱工具各不相同，最常用的是 Fried 虚弱表型和老年评估。炎症参数升高（即白细胞介素 6、中性粒细胞与淋巴细胞比值、格拉斯哥预后评分-2）与虚弱严重程度相关。只有 6 项研究的评估等级为高质量。总之，研究数量少，虚弱评估的异质性限制了我们从现有文献中得出结论的能力。需要进一步研究以确定癌症幸存者虚弱的潜在靶向生物标志物，这可能有助于早期发现和转介。
